Tamoxifen Compared With Clomiphene Citrate for Women Who Had Thin Endometrium Women Under Clomiphene in a Previous Cycle
Sponsored by Shaare Zedek Medical Center
About this trial
Last updated 18 years ago
Study ID
tamoxi vs clomiphene.CTIL
Status
Unknown status
Type
Interventional
Phase
N/A
Placebo
No
Accepting
18 to 35 Years
Female
Not accepting
Healthy Volunteers
Trial Timing
Started 18 years ago
What is this trial about?
About 10-15% of all couples attempting to conceive will not become pregnant within one
year. Among those, the majority will have ovulatory dysfunction, mild male infertility or
unexplained infertility. The traditional first line therapy for those couples is
ovulation induction or superovulation using clomiphene citrate. Probably due to
anti-estrogenic effects of this agent will, some patients will have a thin endometrium as
measured by sonography at the time of ovulation. This phenomenon may be associated with a
lower chance to conceive. Tamoxifen is a similar molecule that has been used to
clomiphene citrate that has been shown to be equally effective to clomiphene in ovulation
induction. Preliminary observations showed that tamoxifen does not cause a negative
effect on the endometrium as compared with clomiphene, and may increase the chance to
conceive in those patients who have a thin endometrium under clomiphene.
What are the participation requirements?
Inclusion Criteria
- Primary or secondary infertility due to:
- Ovulatory dysfunction
- Mild male infertility
- Unexplained infertility
- Endometrium < 6 mm at time of hCG during previous treatment with clomiphene citrate
- Age 18-35
Exclusion Criteria
- Serious adverse effects under clomiphene citrate or known sensitivity to either tamoxifen or clomiphene citrate
Locations
Location
Status
Recruiting